PFE DEF 14A DEF-14A Report March 16, 2023 | Alphaminr
PFIZER INC

PFE DEF 14A Report ended March 16, 2023

PFIZER INC
10-Ks and 10-Qs
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Oct. 1, 2023
10-Q
Quarter ended July 2, 2023
10-Q
Quarter ended April 2, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Oct. 2, 2022
10-Q
Quarter ended July 3, 2022
10-Q
Quarter ended April 3, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Oct. 3, 2021
10-Q
Quarter ended July 4, 2021
10-Q
Quarter ended April 4, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 27, 2020
10-Q
Quarter ended June 28, 2020
10-Q
Quarter ended March 29, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 29, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended July 1, 2018
10-Q
Quarter ended April 1, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Oct. 1, 2017
10-Q
Quarter ended July 2, 2017
10-Q
Quarter ended April 2, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Oct. 2, 2016
10-Q
Quarter ended July 3, 2016
10-Q
Quarter ended April 3, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 27, 2015
10-Q
Quarter ended June 28, 2015
10-Q
Quarter ended March 29, 2015
10-K
Fiscal year ended Dec. 31, 2014
10-Q
Quarter ended Sept. 28, 2014
10-Q
Quarter ended June 29, 2014
10-Q
Quarter ended March 30, 2014
10-K
Fiscal year ended Dec. 31, 2013
10-Q
Quarter ended Sept. 29, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-K
Fiscal year ended Dec. 31, 2012
10-Q
Quarter ended Sept. 30, 2012
10-Q
Quarter ended July 1, 2012
10-Q
Quarter ended April 1, 2012
10-K
Fiscal year ended Dec. 31, 2011
10-Q
Quarter ended Oct. 2, 2011
10-Q
Quarter ended July 3, 2011
10-Q
Quarter ended April 3, 2011
10-K
Fiscal year ended Dec. 31, 2010
10-Q
Quarter ended Oct. 3, 2010
10-Q
Quarter ended July 4, 2010
10-Q
Quarter ended April 4, 2010
10-K
Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
Filed on March 14, 2024
DEF 14A
Filed on March 16, 2023
DEF 14A
Filed on March 17, 2022
DEF 14A
Filed on March 12, 2021
DEF 14A
Filed on March 13, 2020
DEF 14A
Filed on March 14, 2019
DEF 14A
Filed on March 15, 2018
DEF 14A
Filed on March 16, 2017
DEF 14A
Filed on March 15, 2016
DEF 14A
Filed on March 12, 2015
DEF 14A
Filed on March 13, 2014
DEF 14A
Filed on March 14, 2013
DEF 14A
Filed on March 15, 2012
DEF 14A
Filed on March 22, 2011
DEF 14A
Filed on March 16, 2010
TABLE OF CONTENTS
A Letter from Pfizers Chairman & Chief Executive Officer iA Message from Pfizers Lead Independent Director ivNotice of 2023 Annual Meeting and Proxy Statement vOur Business and StrategyItem 1 Election of DirectorsCriteria for Board Membership Our 2023 Director NomineesSelection of Candidates Director NomineesDirector IndependenceGovernanceOverview Governance & Sustainability Committee ReportGovernance Materials Available on Our Website Regulatory and Compliance Committee ReportBoard Leadership Structure Shareholder OutreachThe Boards Role in Risk Oversight Public Policy Engagement and Political ParticipationThe Boards Role in Succession Planning Pfizer Policies on Business ConductEvaluation of Board Effectiveness Other Governance Practices and PoliciesBoard and Committee InformationNon-Employee Director Compensation2022 Director Compensation TableSecurities OwnershipBeneficial OwnersItem 2 Ratification of Selection of Independent Registered Public Accounting FirmAudit and Non-Audit FeesAudit Committee ReportItem 3 2023 Advisory Approval of Executive Compensation2022 Advisory Vote on Executive Compensation 2023 Advisory Vote on Executive Compensation2022 Pay-for-PerformanceItem 4 Advisory Vote on Frequency of Future Advisory Votes to Approve Executive CompensationCompensation Committee ReportExecutive CompensationCompensation Discussion and Analysis Compensation TablesExecutive Summary Financial MeasuresShareholder ProposalsItem 5 Ratification of Termination Pay Item 8 Impact of Extended Patent Exclusivities on Product Access ReportItem 6 Independent Board Chairman Policy Item 9 Political Contributions Congruency ReportItem 7 Transfer of Intellectual Property to Potential COVID-19 Manufacturers Feasibility ReportAnnual Meeting InformationAnnual Meeting Other BusinessVoting Submitting Proxy Proposals and Director Nominations for the 2024 Annual MeetingProxy MaterialsOther Questions